Tigermed

Tigermed is a Chinese biopharmaceutical services company that has been referenced in the context of A+H dual-listing strategies and as an active investor in the biotech sector. In a 2020 discussion on innovative companies navigating listing pathways, it was cited as an example of a quality A-share company that went public in Hong Kong, illustrating the trend of high-market-value red-chip companies returning to domestic markets . More recently, Tigermed participated as a follow-on investor in CoreVision Biopharma's Series A round in July 2024, backing the targeted radiopharmaceutical startup alongside Gaorong Ventures and Liche Capital . Qiming Venture Partners has also listed Tigermed among its portfolio companies in the healthcare sector, alongside Gan & Lee Pharmaceuticals and Zai Lab, as part of its shift from internet-era bets toward more industry-oriented investments .